Bevacizumab (Avastin) as first-line therapy for glioblastoma. This article is based on smaller and earlier trials of adding Avastin to the standard of care for glioblastomas. They report an improvment in progression free survival, but only a small improvement in overall survival. We are eagerly awaiting the results of a much larger study - hopefully in 2-3 months - to clarify how best to use Avastin - either right at the start after radiation or wait until recurrence. Right now we really do not know which way is best.
Having said that, an improvement in progression free survival is still very important. It means that you can function and enjoy life for a longer time, and that is priceless.
The BrainPower 5K in Austin, TX, is this Sunday, Sept. 9 This has nothing to do with the Musella Foundation but they are a good organization and have funded some excellent research! If you are in the area - please participate and help spread the word of the event!